PPD Doubles Personnel For Internal Discovery Of Therapeutic Targets
Executive Summary
PPD has "nearly doubled" the number of full-time equivalents in its discovery unit dedicated to R&D for internal projects, CEO Fred Eshelman, MD, told analysts during an April 17 conference call.
You may also be interested in...
Quintiles/Orion Rx Development Venture Will Start With Three Phase II Drugs
A drug development venture being formed by the contract research organization Quintiles and the Finnish drug manufacturer Orion will start with at least three drugs in Phase II clinical trials
Quintiles/Orion Rx Development Venture Will Start With Three Phase II Drugs
A drug development venture being formed by the contract research organization Quintiles and the Finnish drug manufacturer Orion will start with at least three drugs in Phase II clinical trials
CROs Counting On Biotech Stock Rise, Phase IV Trials To Drive New Business
Recently enriched biotechnology companies will help the contract research organization market recover from its slump in the coming year, PPD CEO Fred Eshelman, MD, told analysts during an April 20 conference call.